The condition, CD3 delta SCID, is caused by a mutation that prevents the production of the CD3 delta protein that is needed for the normal development of T cells
Researchers report that all nine patients who were successfully treated for ADA-SCID in a UCLA clinical trial from 2009 to 2012 are still disease-free.